Skip to main content

Reata Pharmaceuticals has been acquired by Biogen. Please visit www.biogen.com for more information.

Site Search
Reata Pharmaceuticals Inc. logo
  • About Us
    • Leadership
    • Ethics & Compliance
  • Our Science
    • Our Technologies
      • Nrf2 Activators
      • HSP90 Modulators
    • Pipeline
    • Partnering & In-Licensing
  • Diseases We Target
    • Neurology
      • Friedreich's Ataxia
      • Diabetic Peripheral Neuropathic Pain
  • Product
    • Prescribing Information
    • Vermont’s Pharmaceutical Marketer Price Disclosure (short form)
    • Vermont’s Pharmaceutical Marketer Price Disclosure (long form)
  • Our Community
    • Patient Advocacy
    • Clinical Trials
    • Early Access
  • Investors
    • Overview
    • News
    • Events & Presentations
    • Financials
      • Quarterly Results
      • Annual Reports
      • SEC Filings
    • ESG
      • ESG Overview
      • Environmental
      • Social
      • Governance
        • Documents & Charters
        • Committee Composition
        • Contact the Board
    • Annual Meeting
    • Settlement
    • Customizable Email Alerts
  • Careers
  • Contact Us
    • Locations
  • About Us
    • Leadership
    • Ethics & Compliance
  • Our Science
    • Our Technologies
      • Nrf2 Activators
      • HSP90 Modulators
    • Pipeline
    • Partnering & In-Licensing
  • Diseases We Target
    • Neurology
      • Friedreich's Ataxia
      • Diabetic Peripheral Neuropathic Pain
  • Product
    • Prescribing Information
    • Vermont’s Pharmaceutical Marketer Price Disclosure (short form)
    • Vermont’s Pharmaceutical Marketer Price Disclosure (long form)
  • Our Community
    • Patient Advocacy
    • Clinical Trials
    • Early Access
  • Investors
    • Overview
    • News
    • Events & Presentations
    • Financials
      • Quarterly Results
      • Annual Reports
      • SEC Filings
    • ESG
      • ESG Overview
      • Environmental
      • Social
      • Governance
        • Documents & Charters
        • Committee Composition
        • Contact the Board
    • Annual Meeting
    • Settlement
    • Customizable Email Alerts
  • Careers
  • Contact Us
    • Locations
  • Twitter opens in a new window
  • Linkedin opens in a new window
  • Facebook opens in a new window
  • Instagram opens in a new window

Changing the landscape in
Life-Threatening Diseases

At Reata Pharmaceuticals, our mission is to develop innovative therapies that change patients’ lives for the better.

Our Pipeline

Reata’s development programs now have an approved product in addition to creating a robust pipeline of drug candidates for the treatment of serious, life-threatening diseases. Find out more here.

Pipeline
Preclinical
Phase 1
Phase 2
Pivotal
Regulatory Review
FDA Approved
Neurology
Friedreich's Ataxia | SKYCLARYS a Friedreich's Ataxia
SKYCLARYS a
Friedreich's Ataxia | Omaveloxolone in Europe b Friedreich's Ataxia
Omaveloxolone in Europe b
DPNP c | Cemdomespib DPNP c
Cemdomespib
Nrf2 Activator | RTA 415 Nrf2 Activator
RTA 415
Nrf2 Activator | RTA 417 Nrf2 Activator
RTA 417

aSKYCLARYS (omaveloxolone) is approved by the U.S. FDA and not approved by any other regulatory authority outside the U.S. bMarketing Authorisation Application (MAA) submitted in 4Q22 in Europe. cDiabetic peripheral neuropathic pain (DPNP). Reata plans to initiate a Phase 2 trial of Cemdomespib in patients with DPNP in the third quarter of 2023.

Cemdomespib, RTA 415, and RTA 417 are investigational drugs. Safety and efficacy have not been established by any agency.

Dawn of a New Era
Reata Pharmaceuticals Inc. logo
Friedreich’s Ataxia

On February 5, 2021, Reata received a letter from the Friedreich’s ataxia community petitioning that Reata submit a New Drug Application (NDA) for omaveloxolone for the treatment of patients with Friedreich’s ataxia.

Read Reata’s Response To The Petition

*Omaveloxolone is an investigational drug. Safety and efficacy have not been established by any regulatory agency.


alport syndrome

The U.S. Food and Drug Administration (FDA) Accepted for Filing Reata’s
first New Drug Application (NDA) of bardoxolone methyl for the treatment of patients with
chronic kidney disease caused by
Alport Syndrome.

Learn More

*Bardoxolone is an investigational drug. Safety and efficacy have not been established by any regulatory agency.

alport syndrome

The U.S. Food and Drug Administration (FDA) files Reata’s first New Drug Application (NDA) of bardoxolone methyl for the treatment of patients with chronic kidney disease caused by Alport Syndrome. The FDA granted Priority Review for our application.

Learn More

*Bardoxolone is an investigational drug. Safety and efficacy have not been established by any regulatory agency.


Intended for US residents only.

  • Sitemap
  • Legal Message
  • Privacy Notice
  • Social Media Disclosure
  • Contact Us
Powered By Q4 Inc. 5.104.0.1 (opens in new window)

© Reata Pharmaceuticals, Inc., All Rights Reserved. | US-NON-2100018 | 09/2023

Stay Connected Mobile

  • Twitter opens in a new window
  • Linkedin opens in a new window
  • Facebook opens in a new window
  • Instagram opens in a new window